BACKGROUND: A previous report described the presence of autoantibodies against folate receptors in 75% of serum samples from women with a history of pregnancy complicated by a neural-tube defect, as compared with 10% of controls. We sought to confirm this finding in an Irish population, which traditionally has had a high prevalence of neural-tube defects. METHODS: We performed two studies. Study 1 consisted of analysis of stored frozen blood samples collected from 1993 through 1994 from 103 mothers with a history of pregnancy complicated by a neural-tube defect (case mothers), 103 mothers with a history of pregnancy but no complication by a neural-tube defect (matched with regard to number of pregnancies and sampling dates), 58 women who had never been pregnant, and 36 men. Study 2, conducted to confirm that the storage of samples did not influence the folate-receptor autoantibodies, included fresh samples from 37 case mothers, 22 control mothers, 10 women who had never been pregnant, and 9 men. All samples were assayed for blocking and binding autoantibodies against folate receptors. RESULTS: In Study 1, blocking autoantibodies were found in 17% of case mothers, as compared with 13% of control mothers (odds ratio, 1.54; 95% confidence interval [CI], 0.70 to 3.39), and binding autoantibodies in 29%, as compared with 32%, respectively (odds ratio, 0.82; 95% CI, 0.44 to 1.50). Study 2 showed similar results, indicating that sample degradation was unlikely. CONCLUSIONS: The presence and titer of maternal folate-receptor autoantibodies were not significantly associated with a neural-tube defect-affected pregnancy in this Irish population. 2009 Massachusetts Medical Society
BACKGROUND: A previous report described the presence of autoantibodies against folate receptors in 75% of serum samples from women with a history of pregnancy complicated by a neural-tube defect, as compared with 10% of controls. We sought to confirm this finding in an Irish population, which traditionally has had a high prevalence of neural-tube defects. METHODS: We performed two studies. Study 1 consisted of analysis of stored frozen blood samples collected from 1993 through 1994 from 103 mothers with a history of pregnancy complicated by a neural-tube defect (case mothers), 103 mothers with a history of pregnancy but no complication by a neural-tube defect (matched with regard to number of pregnancies and sampling dates), 58 women who had never been pregnant, and 36 men. Study 2, conducted to confirm that the storage of samples did not influence the folate-receptor autoantibodies, included fresh samples from 37 case mothers, 22 control mothers, 10 women who had never been pregnant, and 9 men. All samples were assayed for blocking and binding autoantibodies against folate receptors. RESULTS: In Study 1, blocking autoantibodies were found in 17% of case mothers, as compared with 13% of control mothers (odds ratio, 1.54; 95% confidence interval [CI], 0.70 to 3.39), and binding autoantibodies in 29%, as compared with 32%, respectively (odds ratio, 0.82; 95% CI, 0.44 to 1.50). Study 2 showed similar results, indicating that sample degradation was unlikely. CONCLUSIONS: The presence and titer of maternal folate-receptor autoantibodies were not significantly associated with a neural-tube defect-affected pregnancy in this Irish population. 2009 Massachusetts Medical Society
Authors: D C Shields; P N Kirke; J L Mills; D Ramsbottom; A M Molloy; H Burke; D G Weir; J M Scott; A S Whitehead Journal: Am J Hum Genet Date: 1999-04 Impact factor: 11.025
Authors: Vincent T Ramaekers; Sheldon P Rothenberg; Jeffrey M Sequeira; Thomas Opladen; Nenad Blau; Edward V Quadros; Jacob Selhub Journal: N Engl J Med Date: 2005-05-12 Impact factor: 91.245
Authors: Lawrence C Brody; Mary Conley; Christopher Cox; Peadar N Kirke; Mary P McKeever; James L Mills; Anne M Molloy; Valerie B O'Leary; Anne Parle-McDermott; John M Scott; Deborah A Swanson Journal: Am J Hum Genet Date: 2002-10-16 Impact factor: 11.025
Authors: Keith L Knutson; Christopher J Krco; Courtney L Erskine; Karin Goodman; Linda E Kelemen; Peter J Wettstein; Philip S Low; Lynn C Hartmann; Kimberly R Kalli Journal: J Clin Oncol Date: 2006-08-14 Impact factor: 44.544
Authors: Sheldon P Rothenberg; Maria P da Costa; Jeffrey M Sequeira; Joan Cracco; Jaclyn L Roberts; Jeremy Weedon; Edward V Quadros Journal: N Engl J Med Date: 2004-01-08 Impact factor: 91.245
Authors: Na Yang; Linlin Wang; Richard H Finnell; Zhiwen Li; Lei Jin; Le Zhang; Robert M Cabrera; Rongwei Ye; Aiguo Ren Journal: Birth Defects Res A Clin Mol Teratol Date: 2016-05-11
Authors: A L Boyles; J L Ballard; E B Gorman; D R McConnaughey; R M Cabrera; A J Wilcox; R T Lie; R H Finnell Journal: Hum Reprod Date: 2011-05-15 Impact factor: 6.918
Authors: Kazuya Miyashita; Jens Lutz; Lisa C Hudgins; Dana Toib; Ambika P Ashraf; Wenxin Song; Masami Murakami; Katsuyuki Nakajima; Michael Ploug; Loren G Fong; Stephen G Young; Anne P Beigneux Journal: J Lipid Res Date: 2020-09-18 Impact factor: 5.922
Authors: Camilla Bille; Dorthe Almind Pedersen; Anne-Marie Nybo Andersen; Maria A Mansilla; Jeffrey C Murray; Kaare Christensen; Johnathan L Ballard; Elizabeth B Gorman; Robert M Cabrera; Richard H Finnell Journal: Pediatr Res Date: 2010-03 Impact factor: 3.756
Authors: Jeffrey M Sequeira; Ankuri Desai; Maria I Berrocal-Zaragoza; Michelle M Murphy; Joan D Fernandez-Ballart; Edward V Quadros Journal: PLoS One Date: 2016-03-24 Impact factor: 3.240
Authors: Richard E Frye; Leanna Delhey; John Slattery; Marie Tippett; Rebecca Wynne; Shannon Rose; Stephen G Kahler; Sirish C Bennuri; Stepan Melnyk; Jeffrey M Sequeira; Edward Quadros Journal: Front Neurosci Date: 2016-03-09 Impact factor: 4.677